What Could Send Pfizer Stock Soaring
Pfizer has demonstrated remarkable rallies, with its stock surging over 30% in under two months during in 2021. These swift upswings have rewarded investors with substantial gains. If similar catalysts emerge, Pfizer shares could be poised for another significant advance, building on its track record of rapid, powerful rallies.
Triggers That Could Boost The Stock
- Oncology Blockbusters: New cancer drugs like Padcev (>$3B peak sales) & vepdegestrant (>$1B by 2030) driving growth.
- Obesity Market Drive: Metsera acquisition, valued at $4.9B, targets $100B+ obesity market. (Contested, but PFE pursuing).
- Non-COVID Portfolio: Q2 2025 non-COVID operational revenue up 10%, with $7.2B cost savings by 2027.
PFE stock may swing. A balanced allocation doesn’t. Trefis’ Boston-based, wealth management partner blends strategy and discipline to smooth out market noise.
How Do Financials Look Right Now
It certainly helps if the fundamentals check out. For details on PFE Read Buy or Sell PFE Stock. Below are a few numbers that matter.
- Revenue Growth: 13.5% LTM and -12.4% last 3-year average.
- Cash Generation: Nearly 19.5% free cash flow margin and 26.1% operating margin LTM.
- Valuation: Pfizer stock trades at a P/E multiple of 12.8
| PFE | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 12.8 | 23.6 |
|
|
||
| LTM* Revenue Growth | 13.5% | 5.4% |
| 3Y Average Annual Revenue Growth | -12.4% | 5.2% |
|
|
||
| LTM* Operating Margin | 26.1% | 18.7% |
| 3Y Average Operating Margin | 20.2% | 18.1% |
| LTM* Free Cash Flow Margin | 19.5% | 13.3% |
*LTM: Last Twelve Months
But How Does The Stock Do In Bad Times?
Looking at Pfizer’s stock through tough times shows risk is still real, even with strong fundamentals. It fell about 39% in the Dot-Com Bubble and dropped more sharply by 53% during the Global Financial Crisis. The 2018 correction and Covid pandemic saw declines close to 24% and 29%, respectively. The inflation shock was especially harsh, with Pfizer tumbling over 53%. So, even with the company’s solid profile, market downturns have hit it hard. Quality matters, but during big sell-offs, few stocks escape significant losses.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.